Associate Prof of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital

Search Tweets

Twitter Feed

@akesselheim — 1,205 followers, 294 tweets

Nov 22, 2017

New @washingtonpost Op-Ed with @akapczynski on steps the executive branch could take to lower drug prices for patients: https://t.co/sWjdsahwb2

Nov 20, 2017

@HollyLynchez Thanks! I thought our study was a great demonstration of the possibilities and limitations of “real world data” in demonstrating drug effectiveness. Great work by @FralickMike @JAMAInternalMed https://t.co/FC6Y4ZG4ER

Nov 20, 2017

@HollyLynchez Thanks! I thought our study was a great demonstration of the possibilities and limitations of “real world data” in evaluating drug effectiveness. Great work by @FralickMike https://t.co/tP8aq7w1Ss

Nov 15, 2017

@SteveJoffe @ZacharyBrennan Good point. Accel approval not supposed to be fall back in case your data aren’t good enough for regular approval. Unfortunately not the way it always works in practice. Mfr should have to declare AA vs Reg at time organizing pivotal trial(s).

Show More